A venture capital firm based in Western Europe is entirely specialized in and focused on investing in early-stage oncology drug development companies. Through its oncology-focused funds, the firm has invested in 13 early stage companies, of which 6 were founded by the firm. The firm’s main focus is on European companies, although they will consider US opportunities.
The firm focuses on a wide spectrum of cancer treatment, including but not limited to small molecules, antibodies, gene therapy, cell therapy, and immunotherapy. The firm supports early-stage companies from incubator stage and preclinical through phase 1. The firm prefers to invest in companies that have underlying platform technologies.
The firm can support management teams by being operationally involved on an interim basis in companies located close to the firm, and will frequently set-up companies from scratch with the inventors. The firm can help refine the business plan, R&D plans and provide financial, IP, IT, legal, HR support. If needed, the firm will take up interim-management roles.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment